TY - JOUR
T1 - Serum tartrate-resistant acid phosphatase isoform 5a (TRACP5a) as a potential risk marker in cardiovascular disease
AU - Janckila, Anthony J.
AU - Lin, Hseun Fu
AU - Wu, Yi Ying
AU - Ku, Chih Hung
AU - Yang, Shih Ping
AU - Lin, Wei Shiang
AU - Lee, Su Huei
AU - Yam, Lung T.
AU - Chao, Tsu Yi
N1 - Funding Information:
The authors acknowledge the expert technical assistance of Miss Hsin-Yi Liu. This work was supported in part by the Research Service of the U.S. Department of Veterans Affairs and the Clinical Research Foundation, Inc. (Dr. A. J. Janckila and Dr. L. T. Yam), the Taiwan Department of Defense ( DOD97-14-03 , Dr. W-S Lin), and the Taiwan Department of Health ( DOH-TD-B-111-003 , Dr. T-Y Chao). All authors have no conflicts of interest.
PY - 2011/5/12
Y1 - 2011/5/12
N2 - Objective: This study was undertaken to determine the association between serum tartrate-resistant acid phosphatase 5a (TRACP5a) and cardiovascular disease (CVD) risk. Methods: Four hundred patients were enrolled including, 291 asymptomatic subjects grouped by the number of traditional risk factors, 36 patients undergoing cardiac arteriography, 34 undergoing percutaneous cardiac intervention, and 39 with acute myocardial infarction. Serum was collected at baseline and, in arteriograpy and intervention groups, periodically for 1. week afterward. In addition to laboratory and clinical evaluation for risk assessment, serum TRACP5a, C-reactive protein (CRP) and interleukin-6 (IL-6) were determined. Results: All biomarkers rose with increasing CVD risk. Only serum TRACP5a, logCRP and cholesterol were elevated in symptomatic patients. Serum TRACP5a was higher in men and correlated with age, logCRP, logIL-6 and log-triglycerides, and in symptomatic patients, with the number of diseased coronary arteries. IL-6 and CRP showed acute phase responses, whereas TRACP5a did not change over 1. week after arteriography or intervention. After adjustment for all other variables and risk factors, TRACP5a and logCRP were the only biomarkers to associate with symptomatic disease. TRACP5a was more specific than CRP to predict myocardial infarction among all subjects. Conclusions: Serum TRACP5a is a macrophage-derived inflammation marker associated with CVD risk, and with coronary vessel disease and its severity and may be a useful marker for screening and assessment of CVD risk.
AB - Objective: This study was undertaken to determine the association between serum tartrate-resistant acid phosphatase 5a (TRACP5a) and cardiovascular disease (CVD) risk. Methods: Four hundred patients were enrolled including, 291 asymptomatic subjects grouped by the number of traditional risk factors, 36 patients undergoing cardiac arteriography, 34 undergoing percutaneous cardiac intervention, and 39 with acute myocardial infarction. Serum was collected at baseline and, in arteriograpy and intervention groups, periodically for 1. week afterward. In addition to laboratory and clinical evaluation for risk assessment, serum TRACP5a, C-reactive protein (CRP) and interleukin-6 (IL-6) were determined. Results: All biomarkers rose with increasing CVD risk. Only serum TRACP5a, logCRP and cholesterol were elevated in symptomatic patients. Serum TRACP5a was higher in men and correlated with age, logCRP, logIL-6 and log-triglycerides, and in symptomatic patients, with the number of diseased coronary arteries. IL-6 and CRP showed acute phase responses, whereas TRACP5a did not change over 1. week after arteriography or intervention. After adjustment for all other variables and risk factors, TRACP5a and logCRP were the only biomarkers to associate with symptomatic disease. TRACP5a was more specific than CRP to predict myocardial infarction among all subjects. Conclusions: Serum TRACP5a is a macrophage-derived inflammation marker associated with CVD risk, and with coronary vessel disease and its severity and may be a useful marker for screening and assessment of CVD risk.
KW - Atherosclerosis
KW - Cardiovascular risk
KW - Inflammation
KW - Macrophage
KW - Myocardial infarction
KW - Tartrate-resistant acid phosphatase
UR - http://www.scopus.com/inward/record.url?scp=79954987830&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79954987830&partnerID=8YFLogxK
U2 - 10.1016/j.cca.2011.01.035
DO - 10.1016/j.cca.2011.01.035
M3 - Article
C2 - 21300043
AN - SCOPUS:79954987830
VL - 412
SP - 963
EP - 969
JO - Clinica Chimica Acta
JF - Clinica Chimica Acta
SN - 0009-8981
IS - 11-12
ER -